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ABSTRACT 
The objective of preparing Venlafaxine hydrochloride as sublingual formulations as it is very patient friendly compared to the conventional 
tablets. Sublingual tablet formulation was proposed to be developed for Venlafaxine hydrochloride to enhance the bioavailability by avoiding 
first pass effect. Crospovidone and sodium starch glycolate used as superdisintegrants. Lactose was used as glidant and mannitol as directly 
compressible filler. Microcrystalline cellulose used as tablet disintegrant. Direct compression method found best and easy for  preparing the 
sublingual tablets. Seven formulations (S1-S7) were prepared and evaluated for thickness which ranges from 1.91 to 2.21, hardness ranges 
from 2.6 to 3.4 kg/cm2, friability 0.71% to 0.90%, weight variations, wetting time ranges from 32-69 seconds disintegration time ranges from 
29 to 57 seconds and in vitro drug release ranges from 70.7 to 98%. Formulation F-7 containing crospovidone (15mg) emerged as best 
formulation based on drug release characteristics. From the present study, it can be concluded that the superdisintegrants increased the 
solubility and in vitro drug release of Venlafaxine hydrochloride. Sublingual formulation (tablets) increased the onset of action and 
bioavailability of Venlafaxine Hydrochloride and prevent them from extensive first-pass effect. 
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INTRODUCTION 
In Sublingual route, a drug is administered by the mouth in 
such way that the drug is rapidly absorbed by the blood 
vessels rather than absorbing through gastrointestinal 
tract.[1] Drug releases the content directly into mucosal lining 
of the mouth beneath the tongue.Venlafaxine is an 
antidepressant drug that comes under the class serotonin-
norepinephrine reuptake inhibitor. Venlafaxine is indicated 
for the treatment of depressive illness including depression 
accompanied by anxiety and panic attacks.  
Pre- systemic elimination 
The first-pass effect also called as pre systemic elimination of 
drug is only occurred with oral formulations. When the drug 
absorbed from gastrointestinal track and reaches to liver 
through portal circulation degradation of drug take place.[2] 
Higher the degradation of drug occurred, the less amount of 
drug reaches to blood circulation (systemic) which directly 
affect its bioavailability and if the bioavailability is less than 
it affects onset of action and dosing size of drug. [3]  
 
Objective 
The objective of preparation and evaluation of the Sublingual 
formulation(tablets) to increase the onset of action and 
bioavailability of Venlafaxine Hydrochloride and prevent 
them from extensive first-pass effect. 
MATERIALS AND METHOD 
Materials 
Venlafaxine hydrochloride (Anwita Drugs and chemicals, 
Hyderabad), crospovidone (Chemco laboratories, Rajkot), 
Sodium starch glycolate (HiMedia Laboratories Pvt. Ltd. 
Mumbai), Microcrystalline cellulose (Loba Chemie, Mumbai), 
Magnesium stearate (Remedy Labs, Gujrat), Mannitol (Loba 
Chemie, Mumbai and Talc (Loba Chemie, Mumbai) were used. 
The composition of  FDTs was mentioned in Table 2. 
Method 
 Melting point: Melting point was determined by 
capillary method. It was found to be 213-214°c.  
 Absorption Maxima: The maximum absorption of the 
drug shown at 220nm in phosphate buffer (pH6.8) 
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 Solubility study: Results were mentioned in table 1 
 Calibration curve: The calibration curve was prepared  
in phosphate buffer (pH6.8) at 220 nm. (Figure.1)  
Sublingual tablets of Venlafaxine Hydrochloride were 
prepared by direct compression method.  
RESULTS AND DISCUSSION  
Formulation of all the seven batches of sublingual tablets 
was prepared by changing the concentration of sodium 
starch glycolate and crospovidone. Results of pre-
compression studies were mentioned in Table no3. Hardness 
of tablets was in the range of 2.6 to 3.4 kg/cm2 and friability 
was in the limit of acceptance. Uniformity of weight of all the 
formulations was also within the range. Results of post 
compression studies such as Wetting time, disintegration 
time, and content uniformity reported in Table 4. The in vitro 
drug release of tablets was determined and formulation F7 
showed maximum cumulative percentage drug release in 30 
min. 
 
Figure 1: Calibration curve of Venlafaxine Hydrochloride 
Table1:  Solubility of drug 
S. No. Solvent Solubility(mg/ml) 
1 Water 480 
2 Ethanol 294 
3 pH6.8 buffer 265 
 
Table2: Composition of Sublingual Tablets 
Ingredients F1 F2 F3 F4 F5 F6 F7 
Venlafaxine HCl 25 25 25 25 25 25 25 
SSG --- 5  10  15  --- --- --- 
CP --- --- --- --- 5  10  15 
Mannitol 105 100 95 90 100 95 90 
Sucrose 15 15 15 15 15 15 15 
MCC 50 50 50 50 50 50 50 
Talc 5 5 5 5 5 5 5 
 
Table3: Pre compression parameters 
Parameters F1 F2 F3 F4 F5 F6 F7 
Angle of Repose(o) 21.62 23.07 20.74 20.69 17.87 22.13 17.15 
Bulk density(gm/ml) 0.45 0.43 0.44 0.49 0.47 0.50 0.41 
Tapped 
density(gm/ml) 
0.59 0.54 0.53 0.60 0.55 0.61 0.56 
Carr’s index (%) 22.3 19.5 15.4 17.6 11.9 22.4 14.4 
Hausner’s ratio 1.28 1.23 1.18 1.20 1.12 1.21 1.19 
 
Table 4: Post compression parameters 
Parameters F1 F2 F3 F4 F5 F6 F7 
Diameter(mm) 10.2 10.2 10.6 10.4 10.1 10 10.2 
Hardness(Kg/cm2) 3.4 3.0 2.9 2.7 2.9 2.8 2.6 
Thickness(mm) 2.1 1.94 1.96 1.91 2.21 1.99 1.92 
Friability (%) 0.71 0.76 0.81 0.84 0.73 0.85 0.90 
Weight variation(mg) 199±0.82 198±0.31 199±0.99 198±0.11 199±0.40 198±0.54 199±0.38 
Wetting time 69 46 37 50 36 51 32 
Disintegration time 57 41 32 39 30 44 29 
Content uniformity 99.10 98.87 99.53 99.07 99.77 99.50 99.36 
 
Table 5: In vitro drug release study 
         Time           
Formulation 
code 0 min. 5 min.  10 min. 15 min. 20 min. 25 min.  30 min. 
F1  0 47.5 62.23 67.27 74.62 81.3 88.57 
F2 0 48.46 63.41 70.58 75.63 83.71 92.75 
F3 0 57 78.39 84.22 89.47 92.14 96.29 
F4 0 52 73.11 81.36 84.19 91 96.55 
F5 0 64.5 79.44 85 89.67 94.89 97.28 
F6 0 30.48 37.62 42.61 48 55.7 70.7 
F7 0 59 80.11 86.24 90 94 98 
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Figure 2: In vitro drug release of tablets 
 
 
CONCLUSION 
Sublingual tablets of Venlafaxine hydrochloride were 
successfully prepared. From the present study, it can be 
concluded that the superdisintegrants increased solubility 
and in vitro drug release of Venlafaxine hydrochloride. 
Preparing sublingual formulation (tablets) increased the 
bioavailability of Venlafaxine Hydrochloride and prevent 
them from extensive first-pass effect. 
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